The role of patient expectancy in placebo and nocebo effects in antidepressant trials

Journal of Clinical Psychiatry

Volumn 75, Issue 10, 2014, Pages 1040-1046

  Rutherford, Bret R ^a   Wall, Melanie M ^a   Glass, Andrew ^a   Stewart, Jonathan W ^a  

^a New York State Psychiatric Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DSM-III-R; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NOCEBO EFFECT; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT ATTITUDE; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION; MIDDLE AGED; PATIENT; PSYCHOLOGY; STANDARDS; TIME; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; NOCEBO EFFECT; PATIENTS; PLACEBO EFFECT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84919880698     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08797     Document Type: Article

References (32)

1. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723-733. doi:10.176/api.ajp.2012.12040474 PubMed
2. Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol. 2005;25(suppl 1):S1-S7. doi:10.1097/01.jcp.0162807.84570.6b PubMed
3. Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? the effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom. 2009;78(3):172-181. doi:10.159/0209348 PubMed
4. Sneed JR, Rutherford BR, Rindskopf D, et al. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry. 2008;16(1):65-73. doi:10.1097/JGP.0b013e3181256b1d PubMed
5. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? results from pooled and meta-analyses. J Clin Psychiatry. 2010;71(3):270-279. doi:10.408/JCP.08r04516blu PubMed
6. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161(11):2045-2049. doi:10.176/api.ajp.161.1.2045 PubMed
7. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? a meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40. doi:10.1016/j.euroneuro.208.08.09 PubMed
8. Rutherford BR, Wager TD, Roose SP. Expectancy and the treatment of depression: a review of experimental methodology and effects on patient outcome. Current Psychiatry Reviews. 2010;6(1):1-10. doi:10.2174/15734010790596571
9. Gaudiano BA, Hughes JA, Miller IW. Patients' treatment expectancies in clinical trials of antidepressants versus psychotherapy for depression: a study using hypothetical vignettes. Compr Psychiatry. 2013;54(1):28-33. doi:10.1016/j.compsych.2012.06.03 PubMed
10. Rutherford BR, Marcus SM, Wang P, et al. A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychol Med. 2013;43(5):975-982. doi:10.1017/S032917120182 PubMed
11. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004;130(2):324-340. doi:10.1037/03-2909.130.2.324 PubMed
12. Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622-627. doi:10.101/jama.287.5.62 PubMed
13. Nestoriuc Y, Orav EJ, Liang MH, et al. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res (Hoboken). 2010;62(6):791-799.
14. Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther. 1987;42(3):250-253. doi:10.1038/clpt.1987.142 PubMed
15. Uhlenhuth EH, Rickels K, Fisher S, et al. Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy. Psychopharmacologia. 1966;9(5):392-418. doi:10.107/BF0406450 PubMed
16. Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry. 1998;55(4):334-343. doi:10.101/archpsyc.5.4.34 PubMed
17. McGrath PJ, Stewart JW, Petkova E, et al. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry. 2000;61(7):518-524. doi:10.408/JCP.v61n0710 PubMed
18. Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry. 1984;41(8):782-786. doi:10.101/archpsyc.1984.017901905607 PubMed
19. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163(9):1542-1548. doi:10.176/api.ajp.163.9.1542 PubMed
20. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154(7):963-969. PubMed
21. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160(4):734-740. doi:10.176/api.ajp.160.4.734 PubMed
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
24. Guy W. Clinical Global Impressions. Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
25. Diggle P, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. Oxford, UK: Oxford University Press; 2002.
26. Harville DA. Variance component estimation. JASA. 1977;72:320-340.
27. Zimmerman M, Posternak MA, Ruggero CJ. Impact of study design on the results of continuation studies of antidepressants. J Clin Psychopharmacol. 2007;27(2):177-181. doi:10.1097/JCP.0b013e3180308e1 PubMed
28. Rief W, Nestoriuc Y, Weiss S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1-3):1-8. doi:10.1016/j.jad.209.01.029 PubMed
29. Mundt JC, Greist JH, Jefferson JW, et al. Is it easier to find what you are looking for if you think you know what it looks like? J Clin Psychopharmacol. 2007;27(2):121-125. doi:10.1097/JCP.0b013e3180387820 PubMed
30. Landin R, DeBrota DJ, DeVries TA, et al. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics. 2000;56(1):271-278. doi:10.1/j.06-341X.20.0271.x PubMed
31. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology. 1994;11(1):33-43. doi:10.1038/np.194.63 PubMed
32. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87. doi:10.1016/S06-323(98)0126-7 PubMed